ArticleInternational journal of molecular sciences2026
Dual-Loaded Quercetin-Resveratrol Niosomes: Sustained In Vitro Release and Retained Bioactivity in Hummus During Simulated Gastrointestinal Digestion.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Quercetin (QUE) and resveratrol (RES) have complementary bioactivities but limited aqueous solubility and oral bioavailability. This study developed dual-loaded quercetin-resveratrol niosomes (QR-NIOs) for incorporation into hummus and screened quercetin:resveratrol molar ratios using antioxidant, erythroprotective, and enzyme-inhibition assays. The 50:50 formulation showed the broadest activity profile and produced vesicles with 90.63 ± 3.63% overall encapsulation efficiency, 149 ± 13 nm diameter, 0.21 ± 0.02 polydispersity index, and -34 ± 2 mV ζ-potential. After 24 h, dialysis passage was 51.63%, compared with 80.35% for the unencapsulated mixture. Following simulated intestinal digestion, enriched hummus yielded 5.8 milligrams of gallic acid equivalents per gram of dry weight (mg GAE/g D.W.) and 4.7 milligrams of quercetin equivalents per gram of dry weight (mg QE/g D.W.) in the dialyzable phenolic and flavonoid fractions, respectively, exceeding both controls while retaining antioxidant and enzyme-inhibitory activities. Over 28 days at 4 °C, microbial counts remained below detection limits and the tested pathogens were absent. Overall acceptability (8.23/9) did not differ significantly from commercial hummus. QR-NIO-enriched hummus represents a sensory-compatible functional-food prototype with sustained apparent release and increased intestinal recovery of assay-reactive phenolic and flavonoid compounds; compound-specific and in vivo validation remains necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.